Sona Nanotech’s Cancer Therapy Shows Promising Preclinical Results
Sona Nanotech Inc. has released new preclinical data demonstrating the efficacy of its Targeted Hyperthermia Therapy (THT) in inhibiting tumor growth in an immunotherapy-resistant colorectal cancer model. The study showed that THT, when used in conjunction with a PD-1 inhibitor, resulted in a significant arrest of tumor growth in all test subjects. The therapy enhances immunotherapy effectiveness, positioning Sona as an industry innovator.
This promising result underscores the potential of THT to enhance the effectiveness of existing immunotherapies, positioning Sona as a significant player in cancer treatment innovation. The company is also engaging Proactive Investors North America Inc. to boost its global profile and public awareness.
Sona Nanotech Inc. operates in the biotechnology industry, focusing on developing Targeted Hyperthermia™, a photothermal cancer therapy.
This therapy uses therapeutic heat delivered by infrared light absorbed by gold nanorods to treat solid cancer tumors. The approach aims to stimulate the immune system, shrink tumors, and enhance drug delivery, offering a minimally invasive and cost-effective adjunct to traditional cancer treatments.
Photothermal therapy (PTT) is another cancer therapeutic strategy that mostly utilizes NIR light absorbing agents to eradicate cancer cells by heating. Compared with traditionally used therapeutic methods, PTT displays a series of advantages such as high specificity, minimal invasiveness and high efficiency.
